Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma

PALGA Group

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)–positive in 67–96% of cases. In patients with locally recurrent and metastatic (R/M) AR-positive SDC, androgen deprivation therapy (ADT) has an overall response rate of 18–64.7%. In this study, we describe the efficacy of adjuvant ADT in patients with poor-risk (stage 4a) AR-positive SDC. Methods: This is a retrospective cohort study in which patients with stage 4a AR-positive SDC were offered adjuvant ADT, i.e. bicalutamide, luteinizing hormone-releasing hormone (LHRH) analogue or a combination of these after tumour resection. In the control group, data were collected on patients with stage 4a SDC who underwent a tumour resection but did not receive adjuvant ADT. Results: Twenty-two AR-positive SDC patients were treated with adjuvant ADT for a median duration of 12 months. The control group consisted of 111 SDC patients. After a median follow-up of 20 months in the ADT-treated patients and 26 months in the control group, the 3-year disease-free survival (DFS) was estimated as 48.2% (95% confidence interval [CI] 14.0–82.4%) and 27.7% (95% CI 18.5–36.9%) (P = 0.037). Multivariable Cox regression analysis showed a hazard ratio of 0.138 (95% CI 0.025–0.751, P = 0.022) for DFS and 0.064 (95% CI 0.005–0.764, P = 0.030) for overall survival (OS) in favour of the ADT-treated patients. Conclusion: Poor-risk, AR-positive SDC patients who received adjuvant ADT have a significantly longer DFS compared with patients in the control group, who did not receive adjuvant ADT. For OS, this was just below and above the significance level, in case there was or was no correction for confounders.

Original languageEnglish
Pages (from-to)62-70
Number of pages9
JournalEuropean Journal of Cancer
Volume110
DOIs
Publication statusPublished - Mar 2019

Fingerprint

Salivary Ducts
Androgens
Carcinoma
Androgen Receptors
Confidence Intervals
Disease-Free Survival
Therapeutics
Control Groups
Salivary Gland Neoplasms
Survival
Gonadotropin-Releasing Hormone
Neoplasms
Cohort Studies
Retrospective Studies
Regression Analysis

Keywords

  • Adjuvants
  • Androgen receptors
  • Antineoplastic agents
  • Cohort studies
  • Disease-free survival
  • Hormonal
  • Pharmaceutical
  • Salivary gland neoplasms
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma. / PALGA Group.

In: European Journal of Cancer, Vol. 110, 03.2019, p. 62-70.

Research output: Contribution to journalArticle

@article{bda9d258ca2f4a2ba9dd43722175df00,
title = "Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma",
abstract = "Aim: Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)–positive in 67–96{\%} of cases. In patients with locally recurrent and metastatic (R/M) AR-positive SDC, androgen deprivation therapy (ADT) has an overall response rate of 18–64.7{\%}. In this study, we describe the efficacy of adjuvant ADT in patients with poor-risk (stage 4a) AR-positive SDC. Methods: This is a retrospective cohort study in which patients with stage 4a AR-positive SDC were offered adjuvant ADT, i.e. bicalutamide, luteinizing hormone-releasing hormone (LHRH) analogue or a combination of these after tumour resection. In the control group, data were collected on patients with stage 4a SDC who underwent a tumour resection but did not receive adjuvant ADT. Results: Twenty-two AR-positive SDC patients were treated with adjuvant ADT for a median duration of 12 months. The control group consisted of 111 SDC patients. After a median follow-up of 20 months in the ADT-treated patients and 26 months in the control group, the 3-year disease-free survival (DFS) was estimated as 48.2{\%} (95{\%} confidence interval [CI] 14.0–82.4{\%}) and 27.7{\%} (95{\%} CI 18.5–36.9{\%}) (P = 0.037). Multivariable Cox regression analysis showed a hazard ratio of 0.138 (95{\%} CI 0.025–0.751, P = 0.022) for DFS and 0.064 (95{\%} CI 0.005–0.764, P = 0.030) for overall survival (OS) in favour of the ADT-treated patients. Conclusion: Poor-risk, AR-positive SDC patients who received adjuvant ADT have a significantly longer DFS compared with patients in the control group, who did not receive adjuvant ADT. For OS, this was just below and above the significance level, in case there was or was no correction for confounders.",
keywords = "Adjuvants, Androgen receptors, Antineoplastic agents, Cohort studies, Disease-free survival, Hormonal, Pharmaceutical, Salivary gland neoplasms, Survival",
author = "{PALGA Group} and {van Boxtel}, W. and Locati, {L. D.} and {van Engen-van Grunsven}, {A. C.H.} and C. Bergamini and Jonker, {M. A.} and E. Fiets and S. Cavalieri and S. Tooten and E. Bos and P. Quattrone and {van Herpen}, {C. M.L.} and Verhaegh, {G. W.} and Schalken, {J. A.} and L. Licitra",
year = "2019",
month = "3",
doi = "10.1016/j.ejca.2018.12.035",
language = "English",
volume = "110",
pages = "62--70",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma

AU - PALGA Group

AU - van Boxtel, W.

AU - Locati, L. D.

AU - van Engen-van Grunsven, A. C.H.

AU - Bergamini, C.

AU - Jonker, M. A.

AU - Fiets, E.

AU - Cavalieri, S.

AU - Tooten, S.

AU - Bos, E.

AU - Quattrone, P.

AU - van Herpen, C. M.L.

AU - Verhaegh, G. W.

AU - Schalken, J. A.

AU - Licitra, L.

PY - 2019/3

Y1 - 2019/3

N2 - Aim: Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)–positive in 67–96% of cases. In patients with locally recurrent and metastatic (R/M) AR-positive SDC, androgen deprivation therapy (ADT) has an overall response rate of 18–64.7%. In this study, we describe the efficacy of adjuvant ADT in patients with poor-risk (stage 4a) AR-positive SDC. Methods: This is a retrospective cohort study in which patients with stage 4a AR-positive SDC were offered adjuvant ADT, i.e. bicalutamide, luteinizing hormone-releasing hormone (LHRH) analogue or a combination of these after tumour resection. In the control group, data were collected on patients with stage 4a SDC who underwent a tumour resection but did not receive adjuvant ADT. Results: Twenty-two AR-positive SDC patients were treated with adjuvant ADT for a median duration of 12 months. The control group consisted of 111 SDC patients. After a median follow-up of 20 months in the ADT-treated patients and 26 months in the control group, the 3-year disease-free survival (DFS) was estimated as 48.2% (95% confidence interval [CI] 14.0–82.4%) and 27.7% (95% CI 18.5–36.9%) (P = 0.037). Multivariable Cox regression analysis showed a hazard ratio of 0.138 (95% CI 0.025–0.751, P = 0.022) for DFS and 0.064 (95% CI 0.005–0.764, P = 0.030) for overall survival (OS) in favour of the ADT-treated patients. Conclusion: Poor-risk, AR-positive SDC patients who received adjuvant ADT have a significantly longer DFS compared with patients in the control group, who did not receive adjuvant ADT. For OS, this was just below and above the significance level, in case there was or was no correction for confounders.

AB - Aim: Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)–positive in 67–96% of cases. In patients with locally recurrent and metastatic (R/M) AR-positive SDC, androgen deprivation therapy (ADT) has an overall response rate of 18–64.7%. In this study, we describe the efficacy of adjuvant ADT in patients with poor-risk (stage 4a) AR-positive SDC. Methods: This is a retrospective cohort study in which patients with stage 4a AR-positive SDC were offered adjuvant ADT, i.e. bicalutamide, luteinizing hormone-releasing hormone (LHRH) analogue or a combination of these after tumour resection. In the control group, data were collected on patients with stage 4a SDC who underwent a tumour resection but did not receive adjuvant ADT. Results: Twenty-two AR-positive SDC patients were treated with adjuvant ADT for a median duration of 12 months. The control group consisted of 111 SDC patients. After a median follow-up of 20 months in the ADT-treated patients and 26 months in the control group, the 3-year disease-free survival (DFS) was estimated as 48.2% (95% confidence interval [CI] 14.0–82.4%) and 27.7% (95% CI 18.5–36.9%) (P = 0.037). Multivariable Cox regression analysis showed a hazard ratio of 0.138 (95% CI 0.025–0.751, P = 0.022) for DFS and 0.064 (95% CI 0.005–0.764, P = 0.030) for overall survival (OS) in favour of the ADT-treated patients. Conclusion: Poor-risk, AR-positive SDC patients who received adjuvant ADT have a significantly longer DFS compared with patients in the control group, who did not receive adjuvant ADT. For OS, this was just below and above the significance level, in case there was or was no correction for confounders.

KW - Adjuvants

KW - Androgen receptors

KW - Antineoplastic agents

KW - Cohort studies

KW - Disease-free survival

KW - Hormonal

KW - Pharmaceutical

KW - Salivary gland neoplasms

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85061387751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061387751&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.12.035

DO - 10.1016/j.ejca.2018.12.035

M3 - Article

C2 - 30771738

AN - SCOPUS:85061387751

VL - 110

SP - 62

EP - 70

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -